Luigi Gargiulo, Luciano Ibba, Matteo Bianco, Sara Di Giulio, Alfano Alfano, Ruggero Cascio Ingurgio, . . . Alessandra Narcisi. (2024). Upadacitinib 30 mg for the optimal management of moderate-to-severe atopic dermatitis: A 52-week single-center real-world study. Taylor & Francis Group.
Chicago Style (17th ed.) CitationLuigi Gargiulo, et al. Upadacitinib 30 mg for the Optimal Management of Moderate-to-severe Atopic Dermatitis: A 52-week Single-center Real-world Study. Taylor & Francis Group, 2024.
MLA (9th ed.) CitationLuigi Gargiulo, et al. Upadacitinib 30 mg for the Optimal Management of Moderate-to-severe Atopic Dermatitis: A 52-week Single-center Real-world Study. Taylor & Francis Group, 2024.
Warning: These citations may not always be 100% accurate.